Global Multiple Myeloma Drugs Market 2017-2021

2016-12-27
Price :
Published : Dec-2016
No. of Pages : 86

Multiple myeloma is an abnormal growth and accumulation of plasma cells in the bone marrow leading to malignancy. This can be caused by the overproduction of monoclonal immunoglobulins such as IgG, IgA, IgD, or IgE; or Bence-Jones protein. Under normal conditions, stem cells develop into B lymphocytes, mature in the lymph nodes, and are transported throughout the body. On the entry of foreign substances into the body, these B-cells develop into plasma cells and produce immunoglobulins against the disease. However, in multiple myeloma, the B-cells are damaged and give rise to many malignant plasma cells that produce excessive immunoglobulins of a single type, which the body does not require.

The analysts forecast the global multiple myeloma drugs market to grow at a CAGR of 9.19% during the period 2017-2021.

Covered in this report

This report covers the present scenario and the growth prospects of the global multiple myeloma drugs market for 2017-2021. To calculate the market size, This report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent multiple myeloma.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

The report, Global Multiple Myeloma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Amgen
  • Celgene
  • Johnson & Johnson
  • Novartis
  • Takeda Pharmaceuticals

Other prominent vendors

  • AB Science
  • AbbVie
  • Acceleron Pharma
  • Acetylon Pharmaceuticals
  • Adaptimmune Therapeutics
  • Alexion Pharmaceuticals
  • AmpliMed Corporation
  • Array BioPharma
  • Benovus Bio
  • BioInvent
  • Biokine Therapeutics
  • Biotest
  • bluebird bio
  • Bristol-Meyer Squibb
  • Calithera Biosciences
  • CASI Pharmaceuticals
  • Celldex Therapeutics
  • Cellectar Biosciences
  • Chroma Therapeutics
  • Cleave Biosciences
  • Curis
  • Dicerna Pharmaceuticals
  • Eureka Therapeutics
  • F. Hoffmann-La Roche
  • Geron Corporation
  • GlycoMimetics
  • GlaxoSmithKline
  • ImmunoGen
  • Immunomedics
  • Innate Pharma
  • JW Pharmaceutical
  • Karyopharm Therapeutics
  • Kyowa Hakko Kirin
  • Merck
  • Midatech Pharma
  • Mirna Therapeutics
  • Molecular Partners
  • MorphoSys
  • NOXXON Pharma
  • Oncoceutics
  • Oncolytics Biotech
  • OncoPep
  • Oncopeptides
  • Ono Pharmaceutical
  • Otsuka Pharmaceuticals
  • Patrys
  • PharmaMar
  • Polyphor
  • Prothena Therapeutics
  • Sanofi
  • Sevion Therapeutics
  • Specialised Therapeutics
  • Spectrum Pharmaceutical
  • SymBio Pharmaceuticals
  • TaiGen Biotechnology
  • Tragara Pharmaceuticals
  • Vaxil Therapeutics
  • Vivolux

Market driver

  • Growing demand for biologic therapies
  • For a full, detailed list, view our report

Market challenge

  • Growing popularity of complementary and alternative medicines (CAM)
  • For a full, detailed list, view our report

Market trend

  • Emergence of nanomedicine platform
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : Technavio
More Reports
Title Price Buy Now

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Venezuela

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Venezuela Summary Venezuela ranked 187 out of 190 countries in ease of doing business. In July 2017, rating firm Standard & Poor's downgraded Venezuela's economy to CCC with a negative outlook. Moody's also downgraded its rating to Caa3 with a negative outlook, while Fitch rated it at CCC with a negative outlook. Venezuela is one of the emerging pharmaceutical markets in South America, with a major dependence on imports. However, economic and political turmoil along with inefficient patent laws and drug pricing policies are major barriers. The value of the market was US$12.6 Billion in 2015, having increased from US$5.7 Billion in 2009, at a Compound Annual Growth Rate (CAGR) of 14.1%. Drug prices in Venezuela are ......
$1995

Hepatobiliary Disease Global Clinical Trials Review, H2, 2017

Hepatobiliary Disease Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatobiliary Disease Global Clinical Trials Review, H2, 2017" provides an overview of Hepatobiliary Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatobiliary Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrac......
$2500

Hemostasis Global Clinical Trials Review, H2, 2017

Hemostasis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemostasis Global Clinical Trials Review, H2, 2017" provides an overview of Hemostasis clinical trials scenario. This report provides top line data relating to the clinical trials on Hemostasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials ......
$2500

Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017

Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017" provides an overview of Hepatocellular Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatocellular Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500

Hemochromatosis Global Clinical Trials Review, H2, 2017

Hemochromatosis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemochromatosis Global Clinical Trials Review, H2, 2017" provides an overview of Hemochromatosis clinical trials scenario. This report provides top line data relating to the clinical trials on Hemochromatosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials databa......
$2500

Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017

Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017" provides an overview of Hepatic Encephalopathy clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatic Encephalopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma e......
$2500

Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017

Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017" provides an overview of Hepatorenal Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatorenal Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Cl......
$2500

Hemoglobinopathies Global Clinical Trials Review, H2, 2017

Hemoglobinopathies Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemoglobinopathies Global Clinical Trials Review, H2, 2017" provides an overview of Hemoglobinopathies clinical trials scenario. This report provides top line data relating to the clinical trials on Hemoglobinopathies. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical t......
$2500

Hepatic Injury Global Clinical Trials Review, H2, 2017

Hepatic Injury Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatic Injury Global Clinical Trials Review, H2, 2017" provides an overview of Hepatic Injury clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatic Injury. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Global Clinical Trials Review, H2, 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Global Clinical Trials Review, H2, 2017" provides an overview of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) clinical trials scenario. This report provides top line data relating to the clinical trials on Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.......
$2500